Beigene Ltd (NASDAQ:BGNE)
| 209.36 Delayed Data As of 3:58pm ET |  +0.45 / +0.22%Today’s Change | 114.41 Today|||52-Week Range 256.01 | +26.30% Year-to-Date |
Latest BGNE News | Press Releases
| BeiGene nabs accelerated review in China for pamiparib application Jul 27 / Seeking Alpha - Paid Partner Content | Week In Review: BeiGene Signs $540 Million Deal For China Rights To 3 HBV Candidates Jul 26 / Seeking Alpha - Paid Partner Content |
| Insider Weekends: CEO Of Guess Buys $1 Million Worth Of Stock Jul 27 / Seeking Alpha - Paid Partner Content |
Today’s Trading
| Previous close | 208.91 |
| Today’s open | 209.19 |
| Day’s range | 209.19 - 214.64 |
| Volume | 4,727 |
| Average volume (3 months) | 265,455 |
| Market cap | $20.3B |
Data as of 3:58pm ET, 08/11/2020
Growth & Valuation
| Earnings growth (last year) | -30.32% |
| Earnings growth (this year) | -0.20% |
| Earnings growth (next 5 years) | +24.00% |
| Revenue growth (last year) | +116.59% |
| P/E ratio | NM |
| Price/Sales | 23.21 |
| Price/Book | 14.45 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| TEVATeva Pharmaceutical | -0.15 | -1.26% |
| BBIOBridgeBio Pharma Inc | -0.14 | -0.49% |
| --Immunotech Laborator... | 0.00 | 0.00% |
Data as of 4:34pm ET, 08/11/2020
Financials
| Next reporting date | November 5, 2020 |
| EPS forecast (this quarter) | -$4.21 |
| Annual revenue (last year) | $428.9M |
| Annual profit (last year) | -$950.3M |
| Net profit margin | -221.53% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Beijing, Beijing |
Forecasts
